Primary Liver Lymphoma in a Patient with Chronic Hepatitis C  by Chen, Huan-Wu et al.
242 J Formos Med Assoc | 2006 • Vol 105 • No 3
H.W. Chen, et al
Primary liver lymphoma is a very rare disease and is frequently overlooked as a possible diagnosis. We report
the case of an asymptomatic middle-aged man with chronic hepatitis C who developed primary liver lymphoma
(PLL). A large solitary tumor in the left lobe of the liver was incidentally detected on routine ultrasound
examination. Imaging studies showed mixed iso- and hypoechogenicity with hypoechoic rim, hypodense in
the pre-contrast phase and thick wall enhancement in the post-contrast phase on computed tomographic
study, hypointensity on T1WI, and hyperintensity of the central portion and slightly higher intensity in the
peripheral wall on T2WI. These pictures were different from focal nodular hyperplasia, hepatocellular
carcinoma, cholangiocarcinoma or metastases. Atypical hepatectomy was performed and the pathology of
the hepatic tumor revealed non-Hodgkin’s lymphoma. Systemic staging revealed no evidence of nodal or
bone marrow involvement, so PLL was diagnosed. There was no tumor recurrence more than 4 years after
operation and chemotherapy. PLL should be included in the differential diagnosis of solitary hepatic tumor
in patients who are hepatitis C virus-positive, and who have atypical imaging and no known malignancy or
elevated tumor marker levels. [J Formos Med Assoc 2006;105(3):242–246]
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In Taiwan, hepatocellular carcinoma (HCC) is the
leading cause of cancer death.1 With advances in
imaging technologies, HCC is no longer difficult
to diagnose, particularly when alpha-fetoprotein
(AFP) is elevated and the patient has chronic hep-
atitis B or C. However, primary liver lymphoma
(PLL) is a very rare disease, with fewer than 150
reported cases,2 and it is frequently overlooked
as a possible diagnosis. PLL is not easily differenti-
ated from other hepatic tumors or pseudotumors
by imaging studies and clinical course. We de-
scribe the imaging features and their correlation
with pathologic results and clinical course in an
asymptomatic, middle-aged man with chronic
hepatitis C who developed PLL.
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Case Report
A 55-year-old man with a 4-year history of chronic
hepatitis C underwent routine ultrasonographic
follow-up, which disclosed a solitary and mixed
iso- and hypoechoic mass with hypoechoic rim,
about 7 cm in diameter, in the left hepatic lobe
(Figure 1A). This mass had not been seen on fol-
low-up 3 months previously. He had been well
without any subjective symptom or noticeable
weight loss. Physical examination did not reveal
icteric sclerae, liver pain, vascular spiders on the
skin or lymphadenopathy. Laboratory studies on
admission showed the following results: aspartate
aminotransferase, 35 IU/L (normal, < 37 IU/L);
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tumor was hypodense in the pre-contrast study and
had thick wall enhancement in the post-contrast
study (Figure 1B). Magnetic resonance imaging
(MRI) showed hypointensity in relation to the
liver on T1-weighted imaging (WI), hyperinten-
sity of the central portion on T2WI and slightly
higher intensity in the peripheral wall (Figure 1C).
After Gd-DTPA administration, there was rim en-
hancement between the central low intensity por-
tion and relatively hypointense peripheral wall
alanine aminotransferase, 49 IU/L (normal, < 41
IU/L); alkaline phosphatase, 134 IU/L (normal,
70–250 IU/L); absence of elevated tumor markers
such as AFP (< 20 ng/mL), CA 19-9 (17 U/mL;
normal, < 37 U/mL), prostate specific antigen
(0.7 ng/mL; normal, < 4.0 ng/mL) and carcinoem-
bryonic antigen (1.48 ng/mL; normal, 0–5 ng/mL);
positive antibody for hepatitis C virus (HCV); neg-
ative HBsAg and anti-HBs. An abdominal comput-
ed tomography (CT) scan demonstrated that the
Figure 1. (A) Sonography shows a solid tumor with mixed iso- and
slightly hypoechoic central portion and hypoechoic rim in the
periphery. The margin is well-demarcated. (B) Post-contrast com-
puted tomography scan shows the lesion at the medial segment of
the left lobe with a well-demarcated margin and central low density
with thick rim enhancement. (C) T2-weighted imaging (TR/TE,
2573/80) shows that the lesion is central, hyperintense and has a
peripheral rim. The rim is slightly more hyperintense than the liver
parenchyma. (D) After Gd-DTPA enhancement, the enhanced
portion (lymphoma cells, arrow) is between the central low signal
(tumor necrosis and fibrosis, asterisk) and surrounding peripheral
hypointense rim (edematous hepatocytes, arrowhead). (E) Angi-
ography of the common hepatic artery reveals no neovascularity
but mass effect (arrows), with no peripheral tumor stain in the
venous phase.
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(Figure 1D). No abnormal lesion was detected in
other body organs by preoperative diagnostic im-
aging techniques. Hepatic angiography showed
no significant neovascularity but mass effect (Fig-
ure 1E). Endoscopic examinations of the upper and
lower gastrointestinal tracts were performed but no
abnormality was found.
Because of the rapid growth rate of the tumor
and absence of primary focus, surgical exploration
was performed and atypical hepatectomy was
undertaken. The frozen section revealed a malig-
nant lymphoma; subsequently, splenectomy and
intra-abdominal lymph node biopsy were per-
formed. Grossly, the hepatic mass was a well-
defined, non-encapsulated, grayish white and
soft tumor, measuring 7.5 × 7 × 7 cm (Figure 2A).
Central scarring and necrosis were also noted.
The non-tumor part of the liver parenchyma
showed no cirrhosis and was not remarkable.
Microscopically, the tumor cells were large with
plasmacytoid or immunoblastic appearance (Fig-
ure 2B), and the margin of the tumor was ill-
defined. Immunohistochemical staining of the
tumor tissue was positive for CD20 and leukocyte
common antigen (LCA, CD45), but negative for
CD3. Thus, non-Hodgkin’s diffuse large cell, im-
munoblastic type, B-cell lymphoma was diag-
nosed. The central part of the tumor showed
sclerotic change without tumor cells. The spleen
showed follicular hyperplasia of white pulp with
polymorphous lymphoplasma cells and occasion-
al immunoblastic infiltration. The lymph node
showed the same follicular hyperplasia and plas-
ma cell infiltration.
Systemic staging revealed no evidence of nodal
or bone marrow involvement, so primary liver
lymphoma was diagnosed. The patient received
four courses of combination chemotherapy post-
operatively, which consisted of cyclophospha-
mide, epirubicin, vincristine, and oral predniso-
lone (CEOP). At the last follow-up 4 years after
the operation, he was well without any sign of re-
currence.
Discussion
PLL is defined as an extranodal lymphoma of the
liver without involvement of any other organ. It is
a rare condition which is frequently overlooked as
a possible diagnosis. In Taiwan, HCC is the most
common primary malignant hepatic tumor,1 and
is always suspected first, especially in a patient
who is an HBV or HCV carrier. Morphologically,
HCC may appear as solitary, multiple nodules or
diffusely infiltrative and almost hypervascular.3
The typical features of HCC include hyperattenua-
tion at the early arterial phase of CT scan and an-
giography.4 Larger HCC (> 5 cm in diameter) some-
times show hypoattenuation within the central
portion of the tumor on early CT phase, but most
are hypervascular on angiography.4 Although
some hypervascular HCC may be undetected on
CT or angiography, most undetected tumors are
smaller (< 3 cm).4 Furthermore, among patients
with HCC without elevated AFP, the reported per-
centage of tumors > 5 cm is low, ranging from
only 16% to 25%.5,6
Figure 2.
(A) The hepatic
mass is a well-
defined, non-
encapsulated,
grayish white
and soft tumor.
Central scarring
and necrosis
are also noted.
(B) Pathologic
section shows
that the tumor
cells are large
with plasmacy-
toid or immuno-
blastic appear-
ance, and
immunohisto-
chemistry
reveals diffuse
large B-cell
lymphoma of
the immuno-
blastic type.
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Common hypovascular tumor should be in-
cluded in the differential diagnosis of patients with
solitary liver tumor detected on routine imaging,
including the mass-forming peripheral type of
cholangiocarcinoma, metastatic tumors and, less
commonly, lymphoma. Cholangiocarcinoma aris-
es from the bile duct epithelium and the most com-
mon appearance of the peripheral type on images
is a lobulated, predominantly hypoattenuated
mass in the central portion appearing as fibrosis
and hyperattenuated enhancement in the periph-
ery with focal dilatation of intrahepatic ducts.7,8
However, the tumor in our patient had a regular
border without intrahepatic duct dilatation. Meta-
static tumor with central necrosis, especially colon
cancer, was also suspected in our patient, but no
primary cancer was found on subsequent clinical
examinations.
Benign lesions, such as abscess and focal nod-
ular hyperplasia (FNH), should also be included
in the differential diagnosis of patients with soli-
tary hepatic lesions. FNH is iso- or hypointense
on T1WI, slightly hyper- or isointense on T2WI,
and shows vivid signal homogeneity during the
early phase of dynamic contrast enhancement.9
Central scar appears hyperintense on T2WI and
with enhancement on the delayed phase after
contrast medium administration,9 but the image
of our patient showed central low signal without
significant enhancement. Abscess is another hy-
povascular hepatic tumor that should be included
in the differential diagnosis of patients with soli-
tary hepatic lesions. A well developed abscess may
have a thick wall that engulfs the fluidic central
portion. In our patient, the pattern of CT and MRI
was very similar to this condition;10 however, it was
excluded by the clinical finding of lack of infec-
tious signs.
The least likely tumors that should be included
in the differential diagnosis of solitary liver lesions
are unusual liver tumors such as lymphoma. In
our patient, pathology revealed diffuse immuno-
blastic large B-cell malignant lymphoma. Wide-
spread non-Hodgkin’s lymphoma often involves
the liver, but PLL is very rare.2 Review of the re-
ported cases2,11–14 reveals that PLL should be in-
cluded in the differential diagnosis if the clinical
condition and imaging picture are not typical. The
most common picture of PLL is a solitary and well-
defined tumor, but multiple nodules and/or dif-
fuse infiltrative form may also be found as the
presentation of secondary liver lymphoma.13 The
imaging features of most PLL, as in the present
case, are iso- to hypoechoic on sonography, hy-
podense on pre-contrast, and show rim enhance-
ment on post-contrast enhanced CT.9,12–14 MRI
shows similar findings with Gd-DTPA enhance-
ment; however, three layers of different tissue
characteristics are more clearly demonstrated on
MRI. Correlated with the pathologic findings,
the central part of this tumor has dominantly scle-
rotic change without viable tumor cells; the prom-
inent enhanced portion at the intermediate layer
is chiefly the lymphoma cells; the outermost layer
is comprised of compressed and edematous hepa-
tocytes (Figure 1D).12,13 Little vascularity is seen
on angiography, but mass effect is evident (Fig-
ure 1E). These angiographic findings are sug-
gestive of tumors other than hypovascular HCC,4
cholangiocarcinoma7,8 or metastasis because
peripheral tumor stains or faint neovascularity are
usually present in a large-sized tumor. After exclu-
sion of the more common tumors, therefore, PLL
should be included in the differential diagnosis
even though it is rare.
Hepatitis C is another indicator of the need to
include PLL in the differential diagnosis of soli-
tary tumors. The prevalence of HCV infection was
higher in patients with B-cell non-Hodgkin’s lym-
phoma than in controls.15,16 Mizorogi et al also re-
ported that primary liver involvement was detected
in three of 17 HCV-positive patients, but in none
of 83 HCV-negative patients.16 The frequent as-
sociation with HCV suggests that this virus may
play a role in the pathogenesis of PLL. The evolu-
tion from a benign cryoglobulinemia to a malig-
nant B-cell lymphoma of lymphoplasmacytic
type has been reported.17 Ferri et al proposed that
HCV acts as a triggering factor for immune activa-
tion and can lead to benign or malignant lympho-
proliferative disorders.18 Although HCV has been
shown to be lymphotropic, HCV RNA genomic se-
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quences cannot integrate into the host genome,
which has led to consideration of an indirect mech-
anism of malignant transformation.17 Malignant
lymphoma in HBV carriers was also reported, but
the relationship of HBV and lymphoma is consid-
ered to be independent.19 Scoazec et al suggested
that several characteristics of PLL form a rather
uniform clinical picture, but the viewpoint that
it is a slow progressing disease may be wrong.20
They considered PLL to be the same as other
lymphomas with rapid tumor growth, such as in
our patient whose hepatic tumor grew rapidly
over a 3-month period. The best treatment for PLL
remains unclear, with some clinicians using sur-
gery only, while some prefer chemotherapy alone
or combined with radiotherapy. However, Page et
al considered that surgery alone does not appear
to be sufficient therapy in view of early extrahe-
patic recurrence, and combination chemotherapy
is probably the most appropriate treatment.21
In conclusion, PLL is rare and frequently over-
looked as a possible diagnosis in patients with a
solitary hepatic lesion. Our patient was an HCV-
positive middle-aged male patient without known
malignancy or elevated levels of tumor markers,
a set of clinical conditions that should lead to in-
creased suspicion of PLL in the differential diag-
nosis of solitary hepatic tumor. The combination
of sonography, CT, MRI and angiography may be
useful in distinguishing PLL from other tumors.
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